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Recently an association between cytomegalovirus (CMV)
replication after allogeneic hematopoietic cell trans-
plantation (HCT) and decreased risk of relapse was described
in a cohort of patients with acute myeloid leukemia (AML)
[Blood. 2011;118(5):1402]. We evaluated this proposed
protective effect of CMV replication in a larger cohort of
consecutive patients with AML (n¼761), as well as patients
with acute lymphoblastic leukemia (ALL) (n¼322), chronic
myelogenous leukemia (CML) (n¼646), and lymphoma
(n¼254) who received an allogeneic HCT at the FHCRC
between 1995 and 2005. All patients underwent weekly
surveillance for CMV replication with pp65-antigenemia
through day 100 after HCT. Antiviral therapy with ganciclovir
was initiated after any positive antigenemia. In multivariable
models, CMV antigenemia at any level was associated with
a decreased risk of morphologic relapse by day 100 among
patients with AML (adjusted HR 0.56, 95% CI 0.34-0.91, P ¼
.02), ALL (adjusted HR 0.21, 95% CI 0.05-1.00, P ¼ .05) and
lymphoma (adjusted HR 0.37, 95% CI 0.13-1.02, P ¼ .05) but
not CML (adjusted HR 0.72, 95% CI 0.2-2.3, P ¼ .58). Higher
levels of antigenemia (>10 positive cells, and >10 positive
cells for two consecutive weeks) were not associated with
incremental protection from relapse for any group. The effect
appeared to be independent of acute GvHD (grade 3-4) or
ganciclovir-related neutropenia (ANC< 500). The association
between early CMV reactivation and relapse protection in
patients with acute leukemia and lymphoma persisted at 1
year after HCT (adjusted HR 0.69, 95% CI 0.5-0.9, P¼ .006) but
was undetectable at 3 years. However, there was no differ-
ence in overall survival at either 100 days or 1 year after HCT
among patients with any level of CMV antigenemia
compared to patients with no CMV reactivation. In conclu-
sion, these data demonstrate an association between CMV
reactivation and decreased risk of early relapse among AML,
ALL and lymphoma, but not CML, patients after allogeneic
HCT. Further laboratory investigations are warranted to
deﬁne the mechanisms of this protection.105
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Background: Idiopathic pneumonia syndrome (IPS) is
a severe respiratory complication that can occur in 2-15% of
allogeneic hematopoietic cell transplant (HCT) recipients. IPS
is clinically characterized by widespread alveolar injury, not
caused by infection, cardiac dysfunction, acute renal failure,
or ﬂuid overload. Although current understanding of IPF
pathogenesis is limited, human and animal models of IPS and
acute lung injury suggest that inﬂammatory and ﬁbrotic
pathways may be involved. We investigated whether single
nucleotide polymorphisms (SNPs) in and near candidate
genes previously found to be associated with acute lung
injury may inﬂuence the risk for developing IPS.
Methods: We conducted a genetic association study using
clinical data and DNA from 67 IPS and 783 control patients.
IPS was deﬁned by chart review according to American
Thoracic Society Guidelines. All SNPs within the candidate
gene and +/-50kb identiﬁed from the 1000 Genome Project
were either genotyped using the Affymetrix GeneChip
Genome-Wide SNP 5.0 (n¼470) or the Illumina 1M Quad
(n¼380), or imputed using previously published methods.
All SNPs were analyzed in additive, dominant, and recessive
multivariate genetic models and the Bonferroni method was
used to adjust for multiple comparisons. Association
between the AGT SNPs and plasma AGT levels was evaluated
in an independent cohort of 378 allogeneic HCT patients.
Results: A total of 1277 SNPs (31 genotyped in both cohorts,
293 genotyped in one cohort and imputed in another, 953
imputed in both cohorts) in 8 candidate genes (ACE, AGT,
SP-B, RANTES, DARC, MCP-1, TNFa and TNFR II) were evalu-
ated. Six SNPs in AGT (rs3827749, rs3789666, rs3789667,
rs2478545, rs2478544 and rs1078499, ﬁve out six are
imputed) met the signiﬁcance threshold and were associated
with an increase in IPS risk in a recessive genetic model
(hazard ratio range 3.58 e 4.71, P-value range .001 e .0004).
In an independent cohort, all 6 SNPs were found to be
signiﬁcantly associated with lower plasma AGT levels in the
recessive genetic model (mean AGT levels: homozygous
recessive 17.8 e 22.4 ng/mL, heterozygous and homozygous
wild type 27.3 ng/mL, P-value range .002 e .00001).
Conclusions: These results suggest that renin-angiotensin
system may be involved in the pathogenesis of IPS after
allogeneic HCT.
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